Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to participate before any trial procedures begin
• People who have been confirmed through a tissue sample (biopsy) to have prostate adenocarcinoma (a specific type of prostate cancer), without small cell features
• People whose cancer stage, based on standard medical staging systems, falls within an early, localised range (no spread to lymph nodes or other parts of the body)
• People whose MRI scan confirms the cancer is at an early stage (T1, T2a, T2b, or T2c under AJCC staging)
• People whose biopsy Gleason score is 3+3 or 3+4 (also called Grade Group 1 or 2 — these are lower-risk categories)
• People whose PSA level is 15 ng/ml or below
• People with a general health performance status rated 0 or 1 on the WHO scale (meaning generally active and able to carry out daily activities)
• People whose urinary symptom score (International Prostate Symptom Score) is 10 or below (use of alpha blocker medications is permitted)
• People whose prostate gland, as measured by MRI, has a volume of 70 cc or less
• People who agree not to father a child during the trial treatment period and for 6 months after treatment ends

Who may not be able to join:

• People whose cancer has reached a more advanced local stage (T3a, T3b, or T4) based on clinical assessment or MRI
• People whose MRI shows significant tumour in the transitional zone (a specific inner region of the prostate) (confirm with trial site)
• People whose imaging shows cancer has spread to lymph nodes or other parts of the body
• People whose biopsy Gleason score is 4+3 or higher
• People currently using hormone therapy (androgen deprivation therapy) or other medications known to affect PSA levels
• People for whom it is not possible to have Calypso tracking beacons implanted (small devices used for precise radiation targeting during treatment)
• People with a history of blood cancer or another solid tumour cancer, unless they have been in remission for at least 3 years — with an exception for certain treated non-melanoma skin cancers
• People who have had radiotherapy to the pelvis in the past
• People who have previously had surgery for prostate cancer
• People who have had a transurethral resection of the prostate (TURP) procedure within the 12 weeks before joining the trial
• People who have a hip prosthesis (artificial hip replacement)
• People with serious or active other health conditions that may make the planned radiation treatment inadvisable
• People with significant medical, psychiatric, psychological, family, or geographical circumstances that, in the opinion of the trial investigator, could interfere with treatment, follow-up, or safety

Important: Always verify eligibility with the trial site directly before applying.